Navigation Links
Interventional radiology: Mitigating symptoms, improving quality of life of MS patients
Date:3/25/2012

Researchers report that performing angioplasty (a treatment that involves temporarily inserting and blowing up a tiny balloon inside a clogged artery to help widen it) on veins in the neck and chest is safeand may be an effective way to treat the venous abnormalities found in those with multiple sclerosis and provide symptom relief. The findings were presented at the Society of Interventional Radiology's 37th Annual Scientific Meeting in San Francisco, Calif.

"Our results are important because there are an estimated 400,000 individuals affected by multiple sclerosis in the United States, some of whom experience symptoms that limit their quality of life in several ways. For many, it can be quite debilitating," explained Hector Ferral, M.D., an interventional radiologist at NorthShore University HealthSystem in Evanston, Ill. "These early results show that performing angioplasty on azygos and jugular vein lesions may have a positive impact on the symptoms of those individuals with MS and also could be an effective palliative treatment geared toward improving their quality of life," added Ferral, the study's lead investigator.

"Our experience showed that 95 percent of the individuals we evaluated had venous obstructions, supporting the concept that venous lesions are common in individuals with multiple sclerosis," said Ferral. "Based on follow-up that included ultrasound one week post procedure and clinic visits every three months, our results showed that people who have this treatment are not exposed to fatal risks. It is our belief that portraying venous angioplasty of the azygos and jugular veins as a high-risk procedure is a widespread misconception that needs to be addressed and corrected," he noted. "In addition to these significant safety findings, we noted that angioplasty provided symptomatic benefit in 55 percent of the individuals we treated," said Ferral.

MS is classified as primary progressive, which means a gradually progressive disease without remission; relapsing remitting, which demonstrates acute attacks with intervals of slow improvements in symptoms; or secondary progressive, where a disease that was once relapsing remitting, is now slowly progressing.

This retrospective review examined results of 105 procedures performed in 94 individuals with MS (age range, 26-67 years old; 35 men, 59 women). This study's subgroups included 50 percent relapsing remitting, 39 percent secondary progressive, 6.4 percent primary progressive and 4.2 percent unknown. Jugular and azygos veins were evaluated with selective venography (imaging of veins after injection with a contrast dye) and intravascular ultrasound (a special imaging process that allows the physician to see from inside the blood vessels). Angioplasty was performed if the imaging confirmed reflux, a condition where valves become weak and don't close properly, allowing blood to flow backward, or a greater than 50 percent decrease in the vessel's diameter. If necessary, stents were then used to treat nonresponsive lesions or blockages. These individuals were given blood-thinning medications for six weeks after the treatment.

Ferral's team reported symptomatic improvement in 55 percent of the individuals treated, and 38 percent reported no improvement. Seven percent of patients did not comply with their follow-up visits and were considered to be lost to follow-up.

Close to 60 percent of those with relapsing remitting MS reported improvement in symptoms, the highest of all the subgroups in this study.

"These important results revealed that, for people with multiple sclerosis who experience debilitating symptoms, minimally invasive interventional radiology treatments can be an effective, palliative treatment that also may improve their quality of life," said Ferral.

"As interventional radiologists, our biggest challenge is to bring to the attention of other specialists, especially those physicians specialized in multiple sclerosis, the evidence that venous lesions, often classified as chronic cerebrospinal venous insufficiency or CCSVI, may be a true entity that deserves further attention and serious research," Ferral explained.

The Society of Interventional Radiology stresses the importance for MS patients to continue an on-going dialogue with their neurologists to discuss their treatment care.

In 2011, members of a Society of Interventional Radiology Foundation's Research Consensus Panel noted that evaluating people with multiple sclerosis who have narrowed jugular and azygos veinsand examining the value of widening those veins with angioplastywarranted careful, well-designed research. The multidisciplinary panel indicated that the "mandatory goal" should be through large-scale, pivotal multicenter trials to explore CCSVI.


'/>"/>

Contact: Ellen Acconcia
eacconcia@sirweb.org
703-460-5582
Society of Interventional Radiology
Source:Eurekalert

Related biology news :

1. Society of Interventional Radiology explores IR evidence in patient care
2. IVC filters: Society of Interventional Radiology leads in patient care, safety, research
3. Society of Interventional Radiology member receives award for career contributions
4. Interventional radiologists: Learn about peripheral arterial disease and get moving
5. Society of Interventional Radiology Foundation campaign bolstered by covidien pledge
6. Society of Interventional Radiology findings support PAD care; Legs For Life® gears up
7. Society of Interventional Radiology Foundation welcomes corporate gift from Sirtex Medical
8. Journal of Vascular and Interventional Radiology increases impact, offers new initiatives
9. Fueling interventional radiology growth: SIR Foundation announces Navilyst Medical Pledge
10. Interventional radiologists provide hope in delaying growth, spread of breast cancer
11. Interventional radiology treatment takes blood pressure to new lows -- and results last
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
Breaking Biology News(10 mins):
(Date:12/7/2016)...  Biocom, the association for the California ... of 21 st Century Cures legislation in Congress. The ... 392-26 vote and in the Senate on December 7 by ... Joe Panetta , president & CEO of Biocom: ... millions of patients around the world. The measure culminates three ...
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, ... developing breakthrough immune modulatory medicines, announced today the initiation ... lead therapeutic candidate, LYC-30937- E nteric C oated, ... skin disease that is estimated to affect as many ... , with approximately 1.5 - 3 million cases ...
(Date:12/7/2016)... San Francisco, CA (PRWEB) , ... ... ... genomics leader uBiome is opening applications to an early access program for ... power of metagenomic deep-sequencing with the simultaneous specific enrichment and detection of ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Osteoarthritis ... the Federal Drug Administration (FDA) to consider OA as a serious disease. As ... about the growing population of OA patients, many of whom may experience progressive ...
Breaking Biology Technology: